• Approval marks Venus Remedies’ entry into Argentina for Ceftriaxone, taking total global MAs for the antibiotic to 39
  • Argentina is the 4th-largest pharmaceutical market in Latin America, valued at approximately US$7.3 billion in 2023
  • Approval strengthens Venus Remedies’ growing international anti-infective portfolio amid rising burden of infectious diseases in LATAM

Bangalore : Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has secured marketing authorization from Argentina’s national regulatory authority for its antibiotic, Ceftriaxone. The approval marks a significant milestone in the company’s expansion across Latin America, strengthening its growing international portfolio and taking the total marketing authorizations (MAs) for Ceftriaxone to 39 globally. The development further reinforces Venus Remedies’ commitment to improving access to essential anti-infective therapies while supporting India’s growing role as a reliable supplier of high-quality injectable pharmaceuticals worldwide.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said, “The approval of Ceftriaxone in Argentina represents an important step in strengthening our presence in the Latin American region. Argentina is the fourth-largest pharmaceutical market in Latin America, valued at approximately USD7.3 billion in 2023, making it a strategically important market for high-quality critical care therapies. Ceftriaxone remains a cornerstone antibiotic in the management of several serious bacterial infections, including meningitis, respiratory tract infections, bloodstream infections, and surgical infections, making it a critical therapy in hospital and intensive care settings. This authorization aligns with our focus on delivering clinically relevant and widely accessible anti-infective therapies across global markets.”

The broader Latin American pharmaceutical market continues to demonstrate steady growth, reinforcing the region’s significance for India’s pharmaceutical exports and long-term healthcare partnerships. The overall Latin American pharmaceutical market is estimated at nearly US$91.85 billion in 2024, projected to reach US$ 172.71 billion by 2034, showing a healthy CAGR of 6.52% across the forecast years.

Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, “Securing this marketing authorization in Argentina is a strategically important milestone in our Latin America expansion journey. India exported approximately US$17.5 million worth of pharmaceutical products to Argentina in 2024, while Latin America and the Caribbean accounted for 6.69% of India’s total pharma exports in FY 2024–25. At Venus Remedies, we remain focused on strengthening our presence in such high-potential markets while supporting the broader agenda of improving access to affordable and quality healthcare solutions globally.”

The approval enables Venus Remedies to commercialize Ceftriaxone in Argentina through its established distribution networks, further strengthening its position in hospital-driven critical care injectable markets.

The development also reflects the company’s expanding international footprint across Latin America and reinforces India’s growing reputation as a dependable supplier of high-quality pharmaceutical solutions. Venus Remedies remains committed to regulatory excellence, sustainable growth, and improving access to life-saving therapies for healthcare providers and patients across global markets.